Compare RHI & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | ICUI |
|---|---|---|
| Founded | 1948 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.0B |
| IPO Year | 1994 | 1995 |
| Metric | RHI | ICUI |
|---|---|---|
| Price | $46.41 | $167.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $35.00 | ★ $193.38 |
| AVG Volume (30 Days) | ★ 1.6M | 198.0K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | 0.40 | ★ 1.96 |
| Revenue | ★ $5,378,506,000.00 | $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.14 | $4.44 |
| P/E Ratio | $94.30 | ★ $85.69 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.83 | $113.37 |
| 52 Week High | $46.70 | $192.85 |
| Indicator | RHI | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 77.18 | 55.72 |
| Support Level | $35.08 | $164.09 |
| Resistance Level | N/A | $167.67 |
| Average True Range (ATR) | 1.75 | 4.46 |
| MACD | 1.12 | 0.82 |
| Stochastic Oscillator | 100.00 | 85.94 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.